Health and Economic After-effects in Leicester Tuberculosis Cohort (HEAL-TB)
Quantifying the Short to Long-term Physical, Psychological, and Socioeconomic Consequences of Pulmonary and Extra-pulmonary Tuberculosis in Patients in Leicester: a Longitudinal Cohort Study.
HEAL-TB (Health and Economic After-effects in Leicester Tuberculosis cohort) is a prospective observational study examining recovery among adults with pulmonary and extrapulmonary tuberculosis (TB). The study aims to understand how physical health, mental health, quality of life, daily activity, work and economic wellbeing change during TB treatment and up to 12 months after treatment completion.
Participants may join the study at different stages, from diagnosis until six months after completing TB treatment, and will be followed prospectively until 12 months after treatment completion. The study uses questionnaires, lung function testing, the Incremental Shuttle Walk Test, wrist-worn activity monitoring and information collected during routine clinical care. No experimental treatment is provided and participants continue to receive their usual NHS care.
The study aims to describe recovery over time, compare recovery following pulmonary and extrapulmonary TB, and identify factors associated with persistent health problems or poorer recovery.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
HEAL-TB is a single-centre prospective observational cohort study designed to characterise physical, psychological and socioeconomic recovery among adults with pulmonary and extrapulmonary tuberculosis. Participants may enter the cohort at different stages of the tuberculosis pathway, from diagnosis or early treatment until six months after treatment completion, and complete the assessments applicable from their point of enrolment onwards. Follow-up continues until 12 months after treatment completion.
The study combines patient-reported outcome measures with objective assessments of physical function and routinely collected clinical information. Outcomes include health-related quality of life, mental health, work productivity and socioeconomic wellbeing, perceived recovery, lung function, functional exercise capacity, physical activity, sedentary behaviour and sleep. Relevant clinical records, imaging reports and routine investigation results are also reviewed to provide information on disease severity, treatment, complications and recovery.
The study is primarily descriptive and exploratory. Recovery trajectories will be characterised over time, with exploratory comparisons between pulmonary and extrapulmonary tuberculosis. Clinical and disease-related characteristics will also be explored as potential predictors of persistent impairment and poorer recovery. The study is intended to improve understanding of recovery beyond treatment completion and inform future approaches to follow-up, rehabilitation and supportive care for people affected by tuberculosis.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Jake Bodycot
- Telefonnummer: +447551792221
- E-Mail: jb1071@leicester.ac.uk
Studienorte
-
-
-
Leicester, Vereinigtes Königreich, LE1 5WW
- University Hospitals of Leicester NHS Trust
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adults with pulmonary or extrapulmonary tuberculosis receiving care or follow-up through University Hospitals of Leicester NHS Trust. Participants may enter the cohort at different stages of the tuberculosis treatment and recovery pathway, from diagnosis until six months after treatment completion. Participants will be recruited through the UHL clinical tuberculosis service across Leicester Royal Infirmary, Glenfield Hospital and Leicester General Hospital and followed prospectively from enrolment until the applicable final assessment at 12 months after treatment completion.
Beschreibung
Inclusion Criteria:
- Aged 16 years or above.
- Any sex/gender.
- Pulmonary or extrapulmonary tuberculosis, receiving or having recently completed tuberculosis treatment, with tuberculosis care or follow-up provided through University Hospitals of Leicester NHS Trust. The latest entry point into the cohort is six months after treatment completion.
- Willing and able to provide informed consent to participate in the study.
Exclusion Criteria:
- Expected to move out of the area or unable to attend follow-up visits.
- Prisoners or people under custodial care.
- Currently involved in research or recently involved in other research.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
Pulmonary Tuberculosis
Participants with pulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study. |
|
Extrapulmonary Tuberculosis
Participants with extrapulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Health-related quality of life measured by EQ-5D-5L
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Health-related quality of life assessed using the EQ-5D-5L, including the EQ-5D-5L utility index and EQ Visual Analogue Scale (EQ VAS). Repeated measurements will be used to characterise changes in health-related quality of life during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Depressive symptoms measured by PHQ-9
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Anxiety symptoms measured by GAD-7
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Anxiety symptoms assessed using the Generalized Anxiety Disorder-7 (GAD-7) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Lung function measured by spirometry
Zeitfenster: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
Pre-bronchodilator spirometry including FEV1, FVC, FEV1/FVC ratio and percent predicted values. Repeated measurements will be used to characterise lung-function trajectories during recovery. |
Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
|
Physical activity measured by wrist-worn activity monitor
Zeitfenster: Study entry and applicable follow-up assessments through 6 months after treatment completion
|
Wrist-worn activity monitoring over 7 days to measure daily physical activity, including steps per day and time spent sedentary and in different physical activity intensity levels. |
Study entry and applicable follow-up assessments through 6 months after treatment completion
|
|
Work productivity and activity impairment measured by WPAI
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Work Productivity and Activity Impairment questionnaire assessing work time missed, impairment while working, overall work impairment and activity impairment. Repeated measurements will characterise changes in work productivity and activity during treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Functional exercise capacity measured by Incremental Shuttle Walk Test
Zeitfenster: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
Functional exercise capacity assessed using the Incremental Shuttle Walk Test (ISWT), with total distance walked recorded in metres. |
Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
|
Respiratory-specific quality of life measured by St George's Respiratory Questionnaire
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Respiratory health status assessed using the St George's Respiratory Questionnaire in participants with pulmonary tuberculosis only, measuring respiratory symptoms, activity limitation and psychosocial impacts. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Participant-reported recovery from tuberculosis
Zeitfenster: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Study-specific questions assessing whether participants consider themselves fully recovered from tuberculosis and how their perceived recovery has changed since the previous study visit. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Manish Pareek, University of Leicester
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 1107
- 223512/Z/21/Z (Andere Zuschuss-/Finanzierungsnummer: Wellcome Trust)
- 365242 (Andere Kennung: IRAS)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
There is currently no plan to make individual participant-level data publicly available. Study findings will be disseminated in aggregate form.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .